MedSwitcher
Updated April 2026

FDA Peptide Reclassification Tracker

Stay informed on the FDA's 2026 reclassification of peptides. This live tracker shows which Category 2 peptides are returning to Category 1 and which remain restricted.

14

Returning

to Category 1

5

Restricted

Remains Category 2

19

Total

Category 2 Peptides

Timeline of Key Events

Sept 2023

FDA announces Category 2 reclassification of 19 peptides

Oct 2023 – Dec 2025

Enforcement period — Category 2 peptides restricted from compounding

Jan 2026

FDA begins formal review of Category 2 list

March 2026

First wave of reclassifications announced — 10 peptides return

Ongoing

Remaining peptides under continued review

Peptides Returning to Category 1 14

BPC-157

Returning to Category 1
Healing

Body Protection Compound-157, widely used for gut healing and tissue repair

Gut healingTendon repairAnti-inflammatory
Original ban: Sept 2023 · Reclassified: March 2026

Thymosin Alpha-1

Returning to Category 1
Immune

Immune modulating peptide for T-cell enhancement

Immune supportChronic infectionsCancer adjunct
Original ban: Sept 2023 · Reclassified: March 2026

Thymosin Beta-4 (TB-500)

Returning to Category 1
Healing

Tissue repair and wound healing peptide

Wound healingMuscle repairAnti-inflammatory
Original ban: Sept 2023 · Reclassified: March 2026

CJC-1295

Returning to Category 1
Growth Hormone

GHRH analog for growth hormone stimulation

GH optimizationRecoveryAnti-aging
Original ban: Sept 2023 · Reclassified: March 2026

Ipamorelin

Returning to Category 1
Growth Hormone

Selective growth hormone secretagogue

GH releaseFat lossRecovery
Original ban: Sept 2023 · Reclassified: March 2026

GHK-Cu

Returning to Category 1
Healing

Copper peptide for collagen and wound healing

Skin rejuvenationWound healingHair growth
Original ban: Sept 2023 · Reclassified: March 2026

AOD-9604

Returning to Category 1
Metabolic

HGH fragment 176-191 for fat metabolism

Fat lossCartilage repair
Original ban: Sept 2023 · Reclassified: March 2026

MOTS-C

Returning to Category 1
Metabolic

Mitochondrial peptide for metabolic optimization

Metabolic healthInsulin sensitivity
Original ban: Sept 2023 · Reclassified: March 2026

Sermorelin

Returning to Category 1
Growth Hormone

GHRH analog (FDA-approved as Geref)

GH optimizationAnti-aging
Original ban: Sept 2023 · Reclassified: March 2026

Tesamorelin

Returning to Category 1
Metabolic

FDA-approved GHRH analog (Egrifta)

Visceral fat reductionHIV lipodystrophy
Original ban: Sept 2023 · Reclassified: March 2026

Epithalon

Under Review
Anti-aging

Telomerase-activating peptide for anti-aging

Telomere lengthAnti-aging
Original ban: Sept 2023 · Reclassified: Pending

Dihexa

Under Review
Cognitive

Angiotensin IV analog with cognitive effects

Cognitive enhancementNeuroprotection
Original ban: Sept 2023 · Reclassified: Pending

PE-22-28

Under Review
Cognitive

5-HT1A agonist peptide with antidepressant properties

Mood supportNeuroprotection
Original ban: Sept 2023 · Reclassified: Pending

5-Amino-1MQ

Under Review
Metabolic

NNMT inhibitor for metabolic optimization

Fat metabolismEnergy
Original ban: Sept 2023 · Reclassified: Pending

Peptides Remaining Restricted 5

Selank

Remains Category 2
Cognitive

Synthetic tuftsin analog with anxiolytic properties

AnxietyCognition
Original ban: Sept 2023

Semax

Remains Category 2
Cognitive

ACTH analog with neuroprotective properties

CognitionNeuroprotection
Original ban: Sept 2023

KPV

Remains Category 2
Immune

Alpha-MSH derived anti-inflammatory peptide

Gut inflammationAntimicrobial
Original ban: Sept 2023

Cerebrolysin

Remains Category 2
Cognitive

Brain-derived neurotrophic peptide mixture

NeuroprotectionStroke recovery
Original ban: Sept 2023

VIP (Vasoactive Intestinal Peptide)

Remains Category 2
Immune

Neuropeptide for CIRS and mold illness

CIRS treatmentMold illness
Original ban: Sept 2023

What This Means For You

  • Returning peptides can once again be compounded by 503A and 503B pharmacies
  • Patients with existing prescriptions for returning peptides can resume therapy
  • Restricted peptides remain unavailable through compounding pharmacies
  • The FDA continues reviewing remaining peptides — more may return in future updates

Always consult with your healthcare provider before starting or resuming any peptide therapy.

Back to Peptide Therapy Hub

Don't miss price changes

GLP-1 prices are changing — stay ahead

Foundayo prices may increase — get alerts before they do. Track price drops, shortages, and new switching guidance without checking back manually.

  • Price increase warnings before they hit
  • Savings card and coupon alerts
  • New switching guidance and availability updates

No spam. Unsubscribe anytime. We never share your email.

Medical Disclaimer:This tracker provides information based on public FDA announcements and regulatory updates. It is not a substitute for professional medical advice. Always consult with a licensed healthcare provider before starting or changing any peptide therapy regimen. The FDA's final decisions may vary, and this tracker reflects current public information as of April 2026.